Active — Not RecruitingNot Applicable

Optimizing the Treatment Strategy for Age-related Macular Degeneration

Norway250 participantsStarted 2020-05-20

Plain-language summary

The purpose of this study is to compare two different treatment protocols for wet macular degeneration; the new protocol called "Observe and Plan" against the current standard protocol "Treat and Extend". Studies suggest that patients achieve equally good visual acuity with fewer controls and that they are more satisfied with the new protocol.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * diagnosed age-related macular degeneration according to criteria. * new diagnose of active CNV verified with OCTA or FA / ICGA. * BCVA ≥ 20/200 measured with ETDRS visual acuity chart * written informed consent Exclusion Criteria: * Eyes formerly treated with anti-VEGF, photodynamic therapy, radiation therapy, transpupillary thermotherapy or focal laser photocoagulation involving the macular area. * Geographic atrophy and subretinal fibrosis affecting the patient's visual acuity. * Any other ongoing eye disease that influences patient's visual acuity, such as glaucoma with central vision loss, proliferative diabetic retinopathy, diabetic macular edema or chronic uveitis.

What they're measuring

Visual acuity

Timeframe: 1 year

Visual acuity

Timeframe: 2 years

Trial details

NCT IDNCT04420923

SponsorSt. Olavs Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-09

View on ClinicalTrials.gov More Wet Macular Degeneration trials